The upcoming report from Exelixis (EXEL) is expected to reveal quarterly earnings of $0.51 per share, indicating an increase of 54.6% compared to the year-ago period. Analysts forecast revenues of ...

收市後：January 31 at 7:19:56 PM EST ALAMEDA, Calif., January 28, 2025--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be ...

Below is Validea's guru fundamental report for EXELIXIS INC (EXEL). Of the 22 guru strategies we follow, EXEL rates highest using our Multi-Factor Investor model based on the published strategy of ...

Exelixis (NASDAQ:EXEL) announced Thursday that the U.S. Food and Drug Administration (FDA) no longer plans to conduct an advisory committee meeting as part of its review of the company’s ...

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U ...